MyMD Pharmaceuticals Inc. (MYMD)

The total asset value of MyMD Pharmaceuticals Inc. (MYMD) stood at $ 30 Mln as on 31-Mar-23

The share price of MyMD Pharmaceuticals Inc. (MYMD) is $0.29 (NASDAQ) as of 28-Nov-2023 16:00 EST. MyMD Pharmaceuticals Inc. (MYMD) has given a return of -57.51% in the last 3 years.

MyMD Pharmaceuticals Inc. (MYMD) has a market capitalisation of $ 64 Mln as on 23-Jun-2023. As per Value Research classification, it is a Small Cap company.

The P/B ratio of MyMD Pharmaceuticals Inc. (MYMD) is 3.08 times as on 23-Jun-2023, a 0.21% premium to its peers’ median range of 2.54 times.

Since, TTM earnings of MyMD Pharmaceuticals Inc. (MYMD) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the MyMD Pharmaceuticals Inc. (MYMD) and enter the required number of quantities and click on buy to purchase the shares of MyMD Pharmaceuticals Inc. (MYMD).

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

The CEO & director of Dr. Christopher C. Chapman Jr., M.D.. is MyMD Pharmaceuticals Inc. (MYMD), and CFO & Sr. VP is Mr. Paul M. Rivard Esq..

The promoters of MyMD Pharmaceuticals Inc. (MYMD) have pledged 0% of the total equity as on Mar-23.

Some of the close peers are:

No, TTM profit after tax of MyMD Pharmaceuticals Inc. (MYMD) was $-9 Mln.